NFL Biosciences SA ALNFL
EURONEXT · France · Health Technology
€0.6500-0.04 (-5.80%)
Market closed· · EUR · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · EUR · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Dublin, Sept. 10, 2026 (GLOBE NEWSWIRE) -- The "NFL-101 Sales Forecast, and Market Size Analysis - 2034" has been added to ResearchAndMarkets.com's offering. The report provides a comprehensive assessment of NFL-101 for smoking cessation across the seven major pharmaceutical markets: the United States, Germany, France, Italy, Spain, the United Kingdom, and Japan. The report evaluates the therapy's clinical development, commercial potential, competitive positioning, regulatory milestones, pricing
MONTPELLIER, France, September 08, 2026--Regulatory News: NFL BIOSCIENCES (Euronext Growth Paris – FR0014003XT0 – ALNFL), a biopharmaceutical company developing innovative botanical drugs for the treatment of addictions, announces today that the scientific communication entitled "Baseline IgG1 Levels as a Candidate Predictive Biomarker of NFL-101 Efficacy in Smoking Cessation: A Post-hoc Analysis of the CESTO2 Phase II Randomized Controlled Trial" has been selected for an oral presentation by th
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.